Modeling dropout from adverse event data: Impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 706-718

  Lalovic, Bojan ^a   Hutmacher, Matt ^b   Frame, Bill ^a   Miller, Raymond ^a  

^a PFIZER INC   (United States)

^b ANN ARBOR PHARMACOMETRICS GROUP   (United States)

Author keywords

adverse events models; discrete time survival models; dose titration; Dropout; generalized anxiety disorder; longitudinal data analysis; pregabalin

Indexed keywords

ALPRAZOLAM; LORAZEPAM; PLACEBO; PREGABALIN; VENLAFAXINE;

ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTERNAL VALIDITY; GENERALIZED ANXIETY DISORDER; HUMAN; LONGITUDINAL STUDY; MULTICENTER STUDY (TOPIC); PREDICTION; SIMULATION; SOMNOLENCE;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; KAPLAN-MEIER ESTIMATE; LIKELIHOOD FUNCTIONS; MALE; MARKOV CHAINS; MODELS, STATISTICAL; PATIENT DROPOUTS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955537100     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010370973     Document Type: Article

References (28)

1. Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008 ; 25: 72-90 (Pubitemid 351213928)
2. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002 ; 63 (suppl 8). 24-34 (Pubitemid 34535254)
3. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsycho pharmacol. 2006 ; 16 (suppl 2). S128 - S133
4. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 ; 29: 26-48 (Pubitemid 46415802)
5. Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs. 2003 ; 12: 663-672 (Pubitemid 36512010)
6. Schwarz JB, Gibbons SE, Graham SR, et al. Novel cyclopropyl beta-amino acid analogues of pregabalin and gabapentin that target the alpha2-delta protein. J Med Chem. 2005 ; 48: 3026-3035 (Pubitemid 40548114)
7. Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother. 2006 ; 7: 2139-2154
8. Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs. 2006 ; 20: 685-693 (Pubitemid 44141496)
9. Ito K, Hutmacher M, Liu J, Qiu R, Frame B, Miller R. Exposure-response analysis for spontaneously reported dizziness in pregabalin-treated patient with generalized anxiety disorder. Clin Pharmacol Ther. 2008 ; 84: 127-135 (Pubitemid 351861494)
10. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003 ; 23: 240-249 (Pubitemid 36807791)
11. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006 ; 67: 771-782 (Pubitemid 43946184)
12. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003 ; 160: 533-540 (Pubitemid 41094262)
13. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005 ; 25: 151-158 (Pubitemid 40395093)
14. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 ; 62: 1022-1030 (Pubitemid 41248382)
15. Frame B, Miller R, Hutmacher MM. Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder. J Pharmacokinet Pharmacodyn. 2009 ; 36: 565-584
16. Kasper S, Blagden M, Seghers S, et al. A placebo-controlled study of pregabalin and venlafaxine treatment of GAD. Eur J Neuropsychopharmacol. 2002 ; 12 (suppl 3). S341
17. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther. 1996 ; 60: 619-635 (Pubitemid 27025909)
18. Sheiner LB, Beal LS, Dunne A. Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J Am Stat Assoc. 1997 ; 92: 1235-1244
19. NONMEM Users Guides. Ellicott City, MD: Icon Development Solutions ; 1989-2006 :
20. Singer JD, Willett JB Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford, UK: Oxford University Press ; 2003 :
21. Klein JP, Moeschberger ML Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer ; 1997 :
22. Hosmer DW, Lemeshow S, May S Applied Survival Analysis: Regression Modeling of Time-to-Event Data. 2 nd ed. Hoboken, NJ: Wiley-Interscience ; 2008 :
23. Tableman M, Kim JS Survival Analysis Using S: Analysis of Time-to-Event Data. Boca Raton, FL: Chapman & Hall/CRC ; 2004 :
24. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007 ; 82: 17-20 (Pubitemid 46944205)
25. Snapinn SM, Qi J, Iglewicz B. Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator. Am Stat. 2005 ; 59: 301-307 (Pubitemid 41616828)
26. Procedures Guide. 2 nd ed. Cary, NC: SAS Institute ; 2006 :
27. S-PLUS Programmer's Manual. Seattle, WA: Insightful, Inc ; 2005 :
28. Kowalski KG, McFadyen L, Hutmacher MM, Frame B, Miller R. A two-part mixture model for longitudinal adverse event severity data. J Pharmacokinet Pharmacodyn. 2003 ; 30: 315-336 (Pubitemid 38096186)